Briefly identify your selected chronic health issue and population.  HIV or diabetes. Describe the geographic region and important characteristics of this population. Describe the patterns of the disease in your selected population using the epidemiologic characteristics of person, place, and time.

• Identify one health outcome you would like to improve for the population.
• Briefly summarize current evidence that supports the importance of improving this health outcome.
• Explain what data you would need to collect, and how you would obtain and analyze it. You may choose to collect primary data or use secondary data. Justify your choice.
• Using the “SMART” method, write short- and long-term objectives for the program.
• Identify the stakeholders who should be involved in program planning.
• Identify which program planning model (see Curley, Chapter 7) you selected for your program. Justify your selection of model. Based on the model, explain how you would plan, implement, and evaluate the program.
• Explain any relevant cultural or ethical considerations related to your program design.
• Explain how you would fund the program.
• Describe strategies that would be appropriate for marketing the program.

Briefly explain why the relationship between genotype and phenotype is often complex for quantitative traits

Interactions between eukaryotic cells and their extracellular matrices is known to regulate which of the following? (many choice, select four that apply) mitochondrial fission cell growth Ocell differentiation Ocell migration binary fission Ocell survival

Consider one type of drug class used to treat the type of diabetes you selected. Select a particular class of antidiabetic drug, i.e. Sulfonylureas/DDP-4i, GLP, etc.

• If you select insulin, focus on type of insulin and go in-depth for discussion about kinetics as well, including proper preparation and administration of this drug.

I would expect you to gain solid understanding of following points so it would be great if you can incoporate them in your discussion if applicable:

• Metformin: place in therapy, mechanism of action
• Insulin: Frequency of blood glucose monitoring for new onset Type 1 DM (requiring regular insulin); Role of “basal insulin” PLUS “regular insulin before meals”
• Diabetes and OTHER comorbidities (Nephropathy, Hypertension):
  • How would your prescribing practice be impacted if you are managing anti-diabetes regimen of a patient who is also diagnosed with hypertension. How would you manage patient’s hyertension with therapeutics (BB, ACE-I, Aldasterone Antagonists)? What clinical monitoring and patient education would be warranted?
•  Medications that can cause hyperglycemia (concept of drug-induced hyperglycemia)
• Patient education on “hypoglycemia”: Symptoms recognition, management